Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
Part of Cancer, Digestive system clinical trials.
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (HCC), also called primary liver cancer
- You already had surgery intended to fully remove the cancer (curative resection) and you’ve fully recovered
- Your liver cancer is considered “high risk” to come back, as defined by the study
- You have not had prior whole-body cancer treatment or other liver-focused procedures for this HCC
- Your overall health is good enough for trial treatment (Child-Pugh A and ECOG 0 or 1)
- Your cancer has not spread outside the liver and there is no leftover or returning tumor found
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving tislelizumab (an immunotherapy drug) at different infusion times after surgery can lower the chance of liver cancer coming back in people at high risk of recurrence.
This trial tests whether a combination of two drugs (sintilimab and lenvatinib) given after surgery can help prevent liver cancer from coming back in people who had a tumor growing into the portal vein (a major blood vessel in the liver). You may join if you recently had successful surgery and haven't had other treatments yet.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
This trial studies whether taking tislelizumab alone or with lenvatinib before surgery can shrink recurrent liver cancer and improve outcomes. It may help by treating the cancer earlier (before the tumor is removed).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.